ライフサイエンスコーパス: bronchiolitis obliterans syndrome

1 gnificant risk factor for the development of bronchiolitis obliterans syndrome.

2 rences were observed in the overall onset of bronchiolitis obliterans syndrome.

3 recipients is limited by the development of bronchiolitis obliterans syndrome.

4 y may improve lung function in patients with bronchiolitis obliterans syndrome.

5 the main risk factor for the development of bronchiolitis obliterans syndrome.

6 ection has been linked to the development of bronchiolitis obliterans syndrome.

7 fts due to acute rejection (AR) or developed bronchiolitis obliterans syndrome.

8 reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.

9 ociated with an increased risk of developing bronchiolitis obliterans syndrome.

10 n of epithelial to mesenchymal transition in bronchiolitis obliterans syndrome.

11 ortality after lung transplantation (LTX) is bronchiolitis obliterans syndrome.

12 ng transplant patients prior to diagnosis of bronchiolitis obliterans syndrome.

13 defined as idiopathic pneumonia syndrome or bronchiolitis obliterans syndrome.

14 th chronic lung allograft rejection known as bronchiolitis obliterans syndrome.

15 he surviving study subjects remain free from bronchiolitis obliterans syndrome.

16 d the impact of primary graft dysfunction on bronchiolitis obliterans syndrome.

17 Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the a

18 antly elevated within 3 months of developing bronchiolitis obliterans syndrome (8.3 [1.4-25.1] vs. 3.

19 Among lung transplant recipients, "bronchiolitis obliterans syndrome," a disorder with clin

20 epatitis C viral RNA (HCV RNA), freedom from bronchiolitis obliterans syndrome, acute rejection, and

21 Infants and young children with bronchiolitis obliterans syndrome after lung transplanta

22 Thin-section CT studies in six patients with bronchiolitis obliterans syndrome (age range, 2 months t

23 reported risk factor for the development of bronchiolitis obliterans syndrome, an important cause of

24 smatch model of multiorgan system cGVHD with bronchiolitis obliterans syndrome and a minor MHC mismat

25 study was to investigate the development of bronchiolitis obliterans syndrome and graft loss after L

26 onic lung allograft rejection in the form of bronchiolitis obliterans syndrome and its histopathologi

27 Because current literature suggests bronchiolitis obliterans syndrome and restrictive allogr

28 valuates the current diagnostic criteria for bronchiolitis obliterans syndrome and reviews the epidem

29 rom lung transplant recipients who developed bronchiolitis obliterans syndrome and were compared to s

30 e hypertension, renal dysfunction, diabetes, bronchiolitis obliterans syndrome, and malignancy.

31 nd the first 6 months, bacterial infections, bronchiolitis obliterans syndrome, and survival.

32 tervention in five patients with progressive bronchiolitis obliterans syndrome, anti-TNFalpha treatme

33 Emphysema, female gender, and bronchiolitis obliterans syndrome are risk factors for s

34 odel demonstrated that the increased risk of bronchiolitis obliterans syndrome associated with primar

35 condary end points were overall survival and bronchiolitis obliterans syndrome at 2 years.

36 emic steroids are the standard treatment for bronchiolitis obliterans syndrome (BOS) after allogeneic

37 In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic

38 genetic polymorphisms on the development of bronchiolitis obliterans syndrome (BOS) after lung trans

39 Bronchiolitis obliterans syndrome (BOS) after lung trans

40 Using log-rank test, freedom from bronchiolitis obliterans syndrome (BOS) and graft surviv

41 the internationally recognized definition of bronchiolitis obliterans syndrome (BOS) and longer follo

42 for chronic graft dysfunction manifested as bronchiolitis obliterans syndrome (BOS) and worse posttr

43 Freedom from bronchiolitis obliterans syndrome (BOS) at three years w

44 Development of bronchiolitis obliterans syndrome (BOS) following lung t

45 d for multiorgan system cGVHD and associated bronchiolitis obliterans syndrome (BOS) in a murine mode

46 plant operation on survival and the onset of bronchiolitis obliterans syndrome (BOS) in consecutive l

47 rentiation is associated with development of bronchiolitis obliterans syndrome (BOS) in human lung al

48 after lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients

49 lowing lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients

50 The term bronchiolitis obliterans syndrome (BOS) is a clinical su

51 Bronchiolitis obliterans syndrome (BOS) is a condition o

52 Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in u

53 Chronic allograft rejection manifested as bronchiolitis obliterans syndrome (BOS) is the leading c

54 Bronchiolitis obliterans syndrome (BOS) is the major lim

55 Bronchiolitis obliterans syndrome (BOS) is the major lim

56 Bronchiolitis obliterans syndrome (BOS) is the major obs

57 Bronchiolitis obliterans syndrome (BOS) is the most comm

58 Bronchiolitis obliterans syndrome (BOS) is the primary l

59 allograft dysfunction (CLAD), presenting as bronchiolitis obliterans syndrome (BOS) or restrictive a

60 n (AR) and development of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major lim

61 Bronchiolitis obliterans syndrome (BOS) remains the lead

62 Bronchiolitis obliterans syndrome (BOS) remains the main

63 -obliteration of the allograft airway during bronchiolitis obliterans syndrome (BOS) that occurs afte

64 Bronchiolitis obliterans syndrome (BOS), a condition of

65 ement of six lung transplant recipients with bronchiolitis obliterans syndrome (BOS), a condition pre

66 s limited by infectious complications and by bronchiolitis obliterans syndrome (BOS), a form of chron

67 Bronchiolitis obliterans syndrome (BOS), a process of fi

68 gnized, idiopathic pneumonia syndrome (IPS), bronchiolitis obliterans syndrome (BOS), and bronchiolit

69 ssion to chronic rejection that manifests as bronchiolitis obliterans syndrome (BOS), but no biomarke

70 tive (ELR(+)) CXC chemokines associated with bronchiolitis obliterans syndrome (BOS), but the effect

71 n after lung transplantation, manifesting as bronchiolitis obliterans syndrome (BOS), has become the

72 g to progressive airflow obstruction, termed bronchiolitis obliterans syndrome (BOS), is the major ca

73 man lung allograft rejection, represented by bronchiolitis obliterans syndrome (BOS), is the single m

74 ween these disorders and risk for subsequent bronchiolitis obliterans syndrome (BOS), mortality and g

75 Bronchiolitis obliterans syndrome (BOS), pathognomonic f

76 Bronchiolitis obliterans syndrome (BOS), the clinical co

77 Bronchiolitis obliterans syndrome (BOS), the major cause

78 n the fibro-obliterative lesion found during bronchiolitis obliterans syndrome (BOS), we hypothesized

79 mputed tomography morphology, mortality, and bronchiolitis obliterans syndrome (BOS)-free survival we

80 ejection or infection) (NORMAL POST) or with bronchiolitis obliterans syndrome (BOS).

81 mortality after lung transplantation (LT) is bronchiolitis obliterans syndrome (BOS).

82 The primary endpoint was freedom from bronchiolitis obliterans syndrome (BOS).

83 to play an important role in the etiology of bronchiolitis obliterans syndrome (BOS).

84 hether it correlated with the development of bronchiolitis obliterans syndrome (BOS).

85 irreversible decline in lung function termed bronchiolitis obliterans syndrome (BOS).

86 splantation may contribute to development of bronchiolitis obliterans syndrome (BOS).

87 al owing to chronic allograft failure termed bronchiolitis obliterans syndrome (BOS).

88 e development of chronic rejection, known as bronchiolitis obliterans syndrome (BOS).

89 all airway injury would increase the risk of bronchiolitis obliterans syndrome (BOS).

90 tation and is an established risk factor for bronchiolitis obliterans syndrome (BOS).

91 al outcomes, often due to the development of bronchiolitis obliterans syndrome (BOS).

92 tation remains limited by the development of bronchiolitis obliterans syndrome (BOS).

93 The per-protocol analysis shows incidence of bronchiolitis obliterans syndrome (BOS): 1/43 in the Eve

94 ce of all other causes (currently defined as bronchiolitis obliterans syndrome [BOS]) is considered t

95 ar that patients may develop an obstructive (bronchiolitis obliterans syndrome [BOS]) or a restrictiv

96 A diagnosis of chronic rejection (bronchiolitis obliterans syndrome [BOS]) was made in 191

97 Different clinical phenotypes (bronchiolitis obliterans syndrome [BOS]-neutrophilic BOS

98 transplants is limited by chronic rejection (bronchiolitis obliterans syndrome, BOS).

99 sinophilic BAL predisposed to development of bronchiolitis obliterans syndrome but particularly to re

100 s that CMVIG prophylaxis reduces the risk of bronchiolitis obliterans syndrome, but a controlled tria

101 Acute rejection is a major risk factor for bronchiolitis obliterans syndrome, but noninvasive bioma

102 d a shorter survival and an earlier onset of bronchiolitis obliterans syndrome compared with patients

103 pha as a potential new therapeutic target in bronchiolitis obliterans syndrome deserving of a randomi

104 This resembles bronchiolitis obliterans syndrome developed following hu

105 Adjustment for clinical variables including bronchiolitis obliterans syndrome did not change this re

106 aft-vs-host disease affects the lung tissue, bronchiolitis obliterans syndrome ensues.

107 Secondary outcomes included freedom from bronchiolitis obliterans syndrome (fBOS) and rates of ac

108 nd 30-day mortality, follow-up survival, and bronchiolitis obliterans syndrome-free survival.

109 A trend, however, toward reduced onset of bronchiolitis obliterans syndrome grade 2 or 3 was obser

110 survival in a multivariable model including bronchiolitis obliterans syndrome grade and baseline FEV

111 Patients with bronchiolitis obliterans syndrome had a higher risk of s

112 Bronchiolitis obliterans syndrome has been associated wi

113 o activate fibroblasts in the development of bronchiolitis obliterans syndrome has not been evaluated

114 ted rejection, acute cellular rejection, and bronchiolitis obliterans syndrome; however, the signific

115 enance macrolide therapy in the treatment of bronchiolitis obliterans syndrome in lung transplant rec

116 after heart transplantation, and potentially bronchiolitis obliterans syndrome in lung transplant rec

117 ges to the progress of medical management of bronchiolitis obliterans syndrome include difficulties a

118 tion is associated with an increased risk of bronchiolitis obliterans syndrome independent of acute r

119 Bronchiolitis obliterans syndrome is a fibrotic occlusio

120 Bronchiolitis obliterans syndrome is a major problem for

121 Bronchiolitis obliterans syndrome is caused by a fibropr

122 Bronchiolitis obliterans syndrome is characterized by fi

123 Bronchiolitis obliterans syndrome is the leading cause o

124 Small airway fibrosis (bronchiolitis obliterans syndrome) is the primary obstac

125 ) chronic allograft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limit

126 and were divided into three groups: no CLAD (bronchiolitis obliterans syndrome level 0 [BOS 0]), earl

127 lantation imitate the in vivo development of bronchiolitis obliterans syndrome-like lesions and revea

128 Recent data suggest that bronchiolitis obliterans syndrome may affect up to 6% of

129 o be important in obliterative bronchiolitis/bronchiolitis obliterans syndrome (OB/BOS), which severe

130 onic lung allograft dysfunction manifests as bronchiolitis obliterans syndrome or the recently descri

131 was not a risk factor for the development of bronchiolitis obliterans syndrome or worse overall survi

132 rvival (P = 0.09) and increased freedom from bronchiolitis obliterans syndrome (P = 0.03) was observe

133 sease (P=0.54) nor a subsequent diagnosis of bronchiolitis obliterans syndrome (P=0.70).

134 Bronchiolitis obliterans syndrome remains the leading ca

135 genesis of chronic lung allograft rejection (bronchiolitis obliterans syndrome) remains to be elucida

136 trated that respiratory viral infection is a bronchiolitis obliterans syndrome risk factor and virus-

137 The remaining four patients had bronchiolitis obliterans syndrome scores of 0 compared w

138 iated with a significantly increased risk of bronchiolitis obliterans syndrome stage 1 (grade 1: rela

139 acute rejection, lymphocytic bronchitis, and bronchiolitis obliterans syndrome stage 1, using univari

140 sponse to viruses and in the pathogenesis of bronchiolitis obliterans syndrome, the predominant manif

141 Freedom from bronchiolitis obliterans syndrome was lower, and mortali

142 the association of bronchial dilatation with bronchiolitis obliterans syndrome was significant (P = .

143 s in the six patients with clinically proved bronchiolitis obliterans syndrome were mosaic perfusion

144 hown to be implicated in the pathogenesis of bronchiolitis obliterans syndrome, which is considered t